Searched for
PHARMA MERGER
Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...- Stocks in news: Prime Focus, Groww, GIC RE, Wipro, NykaaIndian benchmark indices traded with a positive bias, with the Nifty consolidating near the 24,000 mark and closing near its day's high. Se...
- Zydus Lifesciences completes acquisition of AssertioThe company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Sun Pharma explores funding mix for $12 billion Organon dealGlobal lenders are exploring various financing options for Sun Pharmaceutical Industries' proposed $12 billion acquisition of Organon & Co....
- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Soleno withdraws EU rare disease drug application ahead of Neurocrine takeoverSoleno Therapeutics has withdrawn its European drug application. This decision stems from its acquirer, Neurocrine Biosciences, prioritizin...
- Medley-Cipla deal talks called off over valuation issuesThis is the second pharma merger and acquisition (M&A) transaction that has been called off or postponed recently due to market volatility ...
- Andhra High Court order not to impact merger with Ranbaxy: Sun PharmaLast week, the court had vacated the status quo order it had issued earlier on the merger process between Sun Pharma and Ranbaxy.
- Andhra HC vacates status quo order on Sun Pharma-Ranbaxy mergerThe Andhra Pradesh high court on Saturday vacated stay orders it issued last month on the merger of two firms that would create world’s fou...
- Andhra HC verdict on Sun Pharma-Ranbaxy merger plea tomorrowThe court had earlier issued interim orders to maintain status quo with regard to the merger.
- SC asks Andhra HC to decide on Ranbaxy-Sun Pharma mergerTwo individual investors alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6.
- Ranbaxy-Sun Pharma merger deal may close by 2014 end: Daiichi SankyoThe $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo said.
Load More
